Jun 2026 (Q2 FY26) — Jul 30, 2026
Phathom Pharmaceuticals Q2 FY26 — First Operating Profit, Strong Revenue Growth, and Pipeline Expansion
Read the full callPhathom Pharmaceuticals (PHAT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Phathom Pharmaceuticals earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 74.3 | +88.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -5.3 | +146.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -17.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$7.5 +1.35% · +$0.1
Performance −40.0% 1Y
1Y: $12.5 on 14 Oct 2025 → $7.5. High $18.08 (7 Jan 2026), low $6.7 (5 Oct 2026).
- Previous close
- $7.4
- 52-week range
- $6.7 – $18.08
- One year
- −44.24%
Overview
- Symbol
- PHAT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Phathom Pharmaceuticals earnings calls (PHAT)
Financials
What the filings say
Net profit, year on year: +77% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 16 | 30 | 29 | 40 | 50 | 58 | 58 | 74 |
| Operating profit | -71 | -59 | -79 | -60 | -15 | -6 | -15 | -4 |
| Operating margin | −432.9% | −200.3% | −276.5% | −151.7% | −30.9% | −10.3% | −26.6% | −5.3% |
| Other income | -15 | -15 | -15 | -16 | -15 | -15 | -15 | -14 |
| Interest | 18 | 19 | 18 | 18 | 16 | 16 | 16 | 15 |
| Net profit | -86 | -74 | -94 | -76 | -30 | -21 | -30 | -18 |
| EPS ($ per share) | -1.32 | — | -1.31 | -1.05 | -0.41 | — | -0.37 | -0.21 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1 | -256 | -385 | -529 | -727 | -929 | -1,263 | -1,484 |
| Total liabilities | 2 | 29 | 101 | 117 | 240 | 487 | 632 | 697 |
| Fixed assets | — | 0 | 1 | 1 | 1 | 2 | 1 | 1 |
| Total assets | 1 | 257 | 295 | 189 | 165 | 414 | 378 | 259 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1 | -37 | -70 | -148 | -147 | -138 | -267 | -167 |
| Cash from investing | — | -25 | -1 | -0 | -1 | -2 | -0 | -0 |
| Cash from financing | 2 | 305 | 114 | 45 | 120 | 368 | 183 | -0 |
| Net cash flow | 1 | 243 | 44 | -104 | -28 | 228 | -84 | -167 |
| Capital expenditure | — | -0 | -1 | -0 | -1 | -2 | -0 | -0 |
| Free cash flow | — | -37 | -71 | -149 | -148 | -139 | -267 | -167 |
Insider filings
39 filings between Nov 3, 2025 and Oct 6, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$7.1K
1 sale by 1 insider
Compensation
not trading decisions- 16
- Award — granted as compensation
- 4
- Option exercise — converted options into shares
- 12
- Tax withheld — shares kept back by the company to cover tax
Also filed: 6 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Breedlove Robert Charles | — | $7.1K | Nov 3, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | Narula Sanjeev Chief Financial & Bus. Officer | Tax withheld | 13,485 | $91.4K |
| Sep 3, 2026 | Breedlove Robert Charles Principal Accounting Officer | Tax withheld | 460 | $4.2K |
| Jul 14, 2026 | Breedlove Robert Charles Principal Accounting Officer | Tax withheld | 1,555 | $17.2K |
| May 22, 2026 | Parikh Asit Director | Gift | 28,000 | $0 |
| May 22, 2026 | Parikh Asit Director | Gift | 28,000 | $0 |
| May 20, 2026 | Parikh Asit Director | Option exercise | 17,500 | $86.6K |
| May 19, 2026 | FIELDS HEIDI Director | Award | 24,122 | $0 |
| May 19, 2026 | Stenhouse Mark Director | Award | 24,122 | $0 |
| May 19, 2026 | Topper James N Director | Award | 24,122 | $0 |
| May 19, 2026 | Parikh Asit Director | Award | 24,122 | $0 |
| May 19, 2026 | Schroeder Theodore R Director | Award | 24,122 | $0 |
| May 19, 2026 | KARBE FRANK Director | Award | 24,122 | $0 |
| May 19, 2026 | COLA MICHAEL F Director | Award | 24,122 | $0 |
| Mar 10, 2026 | Parikh Asit Director | Gift | 40,000 | $0 |
| Mar 10, 2026 | Parikh Asit Director | Gift | 40,000 | $0 |
| Feb 27, 2026 | Breedlove Robert Charles Principal Accounting Officer | Tax withheld | 964 | $12.1K |
| Feb 27, 2026 | Breedlove Robert Charles Principal Accounting Officer | Tax withheld | 414 | $5.2K |
| Feb 27, 2026 | Breedlove Robert Charles Principal Accounting Officer | Award | 13,000 | $0 |
| Feb 27, 2026 | Breedlove Robert Charles Principal Accounting Officer | Award | 2,790 | $0 |
| Feb 10, 2026 | Cook Anne Marie Chief Legal Off. & Corp. Sec. | Award | 3,461 | $0 |
| Feb 10, 2026 | Cook Anne Marie Chief Legal Off. & Corp. Sec. | Tax withheld | 1,535 | $19.7K |
| Feb 10, 2026 | Basta Steven L President and CEO | Tax withheld | 6,277 | $80.5K |
| Feb 10, 2026 | Basta Steven L President and CEO | Award | 12,362 | $0 |
| Jan 23, 2026 | Parikh Asit Director | Gift | 80,500 | $0 |
| Jan 23, 2026 | Parikh Asit Director | Gift | 80,500 | $0 |
| Jan 21, 2026 | Breedlove Robert Charles Principal Accounting Officer | Tax withheld | 776 | $10.6K |
| Jan 13, 2026 | Parikh Asit Director | Option exercise | 8,750 | $90.1K |
| Jan 2, 2026 | Basta Steven L President and CEO | Award | 251,034 | $0 |
| Jan 2, 2026 | Cook Anne Marie Chief Legal Off. & Corp. Sec. | Award | 75,345 | $0 |
| Jan 2, 2026 | Narula Sanjeev Chief Financial & Bus. Officer | Award | 82,715 | $0 |
| Dec 19, 2025 | Parikh Asit Director | Option exercise | 8,750 | $90.1K |
| Dec 18, 2025 | Breedlove Robert Charles Principal Accounting Officer | Tax withheld | 230 | $3.7K |
| Dec 17, 2025 | Basta Steven L President and CEO | Tax withheld | 31,502 | $483.9K |
| Dec 17, 2025 | Cook Anne Marie Chief Legal Off. & Corp. Sec. | Award | 17,370 | $0 |
| Dec 17, 2025 | Cook Anne Marie Chief Legal Off. & Corp. Sec. | Tax withheld | 7,703 | $118.3K |
| Dec 17, 2025 | Basta Steven L President and CEO | Award | 62,038 | $0 |
| Nov 28, 2025 | Basta Steven L President and CEO | Tax withheld | 48,375 | $755.6K |
| Nov 28, 2025 | Basta Steven L President and CEO | Option exercise | 90,000 | $0 |
| Nov 3, 2025 | Breedlove Robert Charles Principal Accounting Officer | Sale | 524 | $7.1K |
| Oct 6, 2025 | Narula Sanjeev Chief Financial & Bus. Officer | Award | 144,000 | $0 |
| Sep 25, 2025 | Basta Steven L President and CEO | Option exercise | 90,000 | $0 |
| Sep 25, 2025 | Basta Steven L President and CEO | Tax withheld | 48,375 | $564.1K |
| Sep 5, 2025 | Breedlove Robert Charles Principal Accounting Officer | Sale | 461 | $5.6K |
| Jul 16, 2025 | Breedlove Robert Charles Principal Accounting Officer | Sale | 1,692 | $14.2K |
| Jun 3, 2025 | FIELDS HEIDI Director | Award | 10,500 | $0 |
| Jun 3, 2025 | Topper James N Director | Award | 10,500 | $0 |
| Jun 3, 2025 | COLA MICHAEL F Director | Award | 10,500 | $0 |
| Jun 3, 2025 | KARBE FRANK Director | Award | 10,500 | $0 |
| Jun 3, 2025 | Parikh Asit Director | Award | 10,500 | $0 |
| Jun 3, 2025 | Stenhouse Mark Director | Award | 10,500 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Phathom Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Phathom Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading